Fig. 3From: Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)MSQv2 outcomes and mapped utilities for patients in BHV3000–201. EF = Emotional Function, EQ-5D = EuroQoL five-dimension, MSQ = migraine specific questionnaire, QALY = quality adjusted life year, RP = Role Function-Preventive, RR = Role Function-RestrictiveBack to article page